人脐带间充质干细胞治疗失代偿性肝硬化患者的初步研究

目的评价人脐带间充质干细胞(UC-MSCs)治疗失代偿性肝硬化的安全性及临床疗效。方法采用平行对照、单盲法将26例失代偿性肝硬化患者进行分组,其中20例为治疗组,接受UC-MSCs外周静脉回输治疗;6例为对照组,给予0.9%NaCl溶液回输,两组均同时行综合内科治疗。测定回输后不同时间点治疗组与对照组白蛋白(Alb)、下腹腹水及终末期肝病模型(MELD)评分的变化。结果 UC-MSCs回输后,除个别患者体温有自限性升高外,无其他不良反应。接受UC-MSCs回输48周后,Alb较治疗前显著升高、腹水较治疗前显著减少(P<0.05);随访末,两组腹水情况比较,差异有统计学意义(P<0.05),但MELD评分差异无统计学意义(P>0.05)。结论人UC-MSCs治疗失代偿性肝硬化患者安全性好,能减轻患者的临床症状,减少腹水形成。

The effect of human umbilical cord derived-mesenchymal stem cells transplantation on patients with decompensated liver cirrhosis:a prospective and control trial

Objective To evaluate the safety and therapeutic efficiency of human umbilical cord derived-mesenchymal stem cells(UC-MSCs) treating patients with decompensated liver cirrhosis.Methods UC-MSCs were identified by morphology,surface markers and differentiation potential which were transplanted into patients with decompensated liver cirrhosis intravenously.The serum Alb,ascites and MELD scores were detected at different time points after UC-MSCs transplantation.Results The quality of life in most patients transplanted with UC-MSCs were improved to varying degrees.Beside low-grade fever in few patients,no other side effects or oncogenecity was found.It was found that the Alb levels were significantly increased while the ascites were significantly decreased.But MELD scores were not significantly decreased after 48w transplatation in patients with decompensated liver cirrhosis underlying UC-MSCs treatment.In addition,the index of the ascites was found to be changed more pronouncedly in the UC-MSCs group as compared with the control groups.Conclusion UC-MSCs transplantation displayed good safety and efficiency in patients with decompensated liver cirrhosis in clinic.